3/19
04:55 pm
rani
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Low
Report
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
3/19
04:05 pm
rani
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
Low
Report
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
3/17
12:20 pm
rani
Surf Therapeutics Reports Positive First-in-Human Data and Secures Additional Financing, Bringing Total Funding to $6M as Rheumatoid Arthritis Clinical Study Begins [Yahoo! Finance]
Low
Report
Surf Therapeutics Reports Positive First-in-Human Data and Secures Additional Financing, Bringing Total Funding to $6M as Rheumatoid Arthritis Clinical Study Begins [Yahoo! Finance]
1/28
10:48 am
rani
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer [Yahoo! Finance]
Medium
Report
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer [Yahoo! Finance]
1/28
07:00 am
rani
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
Medium
Report
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
1/9
08:02 am
rani
Rani Therapeutics (NASDAQ:RANI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Low
Report
Rani Therapeutics (NASDAQ:RANI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
1/8
07:00 am
rani
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
Low
Report
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
12/30
04:14 pm
rani
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.